PEG-rIL-10 treatment decreases FoxP3+ Tregs despite upregulation of intratumoral IDO

OncoImmunology

Volumn 5, Issue 7, 2016, Pages

  Chan, Ivan H ^a   Wu, Victoria ^a   Bilardello, Melissa ^a   Jorgenson, Brett ^a   Bal, Harminder ^a   McCauley, Scott ^a   Van Vlasselaer, Peter ^a   Mumm, John B ^a  

^a ARMO Biosciences   (United States)

Author keywords

FoxP3+; IDO; IL 10; IL 2; immunoncology; Treg polarization; TGF

Indexed keywords

AM 0010; KYNURENINE; RECOMBINANT INTERLEUKIN 10; STAT3 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TRYPTOPHAN; UNCLASSIFIED DRUG;

ANALYSIS OF VARIANCE; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG DOSE ESCALATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE; POLARIZATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; TUMOR ASSOCIATED LEUKOCYTE;

EID: 84978513773     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1197458     Document Type: Article

References (43)

1. R.de Waal Malefyt, J.Abrams, B.Bennett, C.G.Figdor, J.E.de Vries. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes:an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174:1209-20; PMID:1940799; http://dx.doi.org/10.1084/jem.174.5.1209
2. R.de Waal Malefyt, J.Haanen, H.Spits, M.G.Roncarolo, A.te Velde, C.Figdor, K.Johnson, R.Kastelein, H.Yssel, J.E.de Vries. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med 1991; 174:915-24; PMID:1655948; http://dx.doi.org/10.1084/jem.174.4.915
3. C.A.Akdis, A.Joss, M.Akdis, A.Faith, K.Blaser. A molecular basis for T cell suppression by IL-10:CD28-associated IL-10 receptor inhibits CD28 tyrosine phosphorylation and phosphatidylinositol 3-kinase binding. FASEB J:Off Pub Federat Am Soc Exp Biol 2000; 14:1666-8; PMID:10973911; http://dx.doi.org/10.1096/fj.99-0874fje
4. A.Joss, M.Akdis, A.Faith, K.Blaser, C.A.Akdis. IL-10 directly acts on T cells by specifically altering the CD28 co-stimulation pathway. Euro J Immunol 2000; 30:1683-90; PMID:10898505; http://dx.doi.org/10.1002/1521-4141(200006)30:6%3c1683::AID-IMMU1683%3e3.0.CO;2-A
5. M.R.Opp, E.M.Smith, T.K.Hughes, Jr. Interleukin-10 (cytokine synthesis inhibitory factor) acts in the central nervous system of rats to reduce sleep. J Neuroimmunol 1995; 60:165-8; PMID:7642744; http://dx.doi.org/10.1016/0165-5728(95)00066-B
6. M.Aste-Amezaga, X.Ma, A.Sartori, G.Trinchieri. Molecular mechanisms of the induction of IL-12 and its inhibition by IL-10. J Immunol 1998; 160:5936-44; PMID:9637507
7. T.K.Varma, T.E.Toliver-Kinsky, C.Y.Lin, A.P.Koutrouvelis, J.E.Nichols, E.R.Sherwood. Cellular mechanisms that cause suppressed gamma interferon secretion in endotoxin-tolerant mice. Infect Immun 2001; 69:5249-63; PMID:11500393; http://dx.doi.org/10.1128/IAI.69.9.5249-5263.2001
8. L.M.Zheng, D.M.Ojcius, F.Garaud, C.Roth, E.Maxwell, Z.Li, H.Rong, J.Chen, X.Y.Wang, J.J.Catino et al. Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med 1996; 184:579-84; PMID:8760811; http://dx.doi.org/10.1084/jem.184.2.579
9. H.Sun, P.Gutierrez, M.J.Jackson, N.Kundu, A.M.Fulton. Essential role of nitric oxide and interferon-gamma for tumor immunotherapy with interleukin-10. J Immunother 2000; 23:208-14; PMID:10746547; http://dx.doi.org/10.1097/00002371-200003000-00005
10. H.Sun, M.J.Jackson, N.Kundu, A.M.Fulton. Interleukin-10 gene transfer activates interferon-gamma and the interferon-gamma-inducible genes Gbp-1/Mag-1 and Mig-1 in mammary tumors. Int J Cancer J Int du Cancer 1999; 80:624-9; PMID:9935167; http://dx.doi.org/10.1002/(SICI)1097-0215(19990209)80:4%3c624::AID-IJC23%3e3.0.CO;2-9
11. H.Groux, F.Cottrez, M.Rouleau, S.Mauze, S.Antonenko, S.Hurst, T.McNeil, M.Bigler, M.G.Roncarolo, R.L.Coffman. A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells. J Immunol 1999; 162:1723-9; PMID:9973435
12. S.Fujii, K.Shimizu, T.Shimizu, M.T.Lotze. Interleukin-10 promotes the maintenance of antitumor CD8(+) T-cell effector function in situ. Blood 2001; 98:2143-51; PMID:11568001; http://dx.doi.org/10.1182/blood.V98.7.2143
13. R.M.Berman, T.Suzuki, H.Tahara, P.D.Robbins, S.K.Narula, M.T.Lotze. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. J Immunol 1996; 157:231-8; PMID:8683120
14. T.Suzuki, H.Tahara, S.Narula, K.W.Moore, P.D.Robbins, M.T.Lotze. Viral interleukin 10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local anergy to allogeneic and syngeneic tumors. J Exp Med 1995; 182:477-86; PMID:7629507; http://dx.doi.org/10.1084/jem.182.2.477
15. J.Emmerich, J.B.Mumm, I.H.Chan, D.LaFace, H.Truong, T.McClanahan, D.M.Gorman, M.Oft. IL-10 directly activates and expands tumor-resident CD8(+) T cells without de novo infiltration from secondary lymphoid organs. Cancer Res 2012; 72:3570-81; PMID:22581824; http://dx.doi.org/10.1158/0008-5472.CAN-12-0721
16. J.B.Mumm, J.Emmerich, X.Zhang, I.Chan, L.Wu, S.Mauze, S.Blaisdell, B.Basham, J.Dai, J.Grein et al. IL-10 elicits IFNgamma-dependent tumor immune surveillance. Cancer Cell 2011; 20:781-96; PMID:22172723; http://dx.doi.org/10.1016/j.ccr.2011.11.003
17. J.R.Infante, A.Naing, K.P.Papadopoulos, K.A.Autio, P.A.Ott, D.J.L.Wong, G.S.Falchook, M.R.Patel, S.Pant, M.Whiteside et al. A first-in-human dose escalation study of PEGylated recombinant human IL-10 (AM0010) in advanced solid tumors. ASCO Meeting Abstracts 2015; 33:3017
18. A.L.Mellor, D.H.Munn. IDO expression by dendritic cells:tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4:762-74; PMID:15459668; http://dx.doi.org/10.1038/nri1457
19. D.H.Munn, A.L.Mellor. IDO and tolerance to tumors. Trends Mol Med 2004; 10:15-8; PMID:14720581; http://dx.doi.org/10.1016/j.molmed.2003.11.003
20. L.Huang, L.Li, K.D.Klonowski, S.M.Tompkins, R.A.Tripp, A.L.Mellor. Induction and role of indoleamine 2,3 dioxygenase in mouse models of influenza a virus infection. PloS One 2013; 8:e66546; PMID:23785507; http://dx.doi.org/10.1371/journal.pone.0066546
21. J.B.Sakash, G.I.Byrne, A.Lichtman, P.Libby. Cytokines induce indoleamine 2,3-dioxygenase expression in human atheroma-associated cells:implications for persistent Chlamydophila pneumoniae infection. Infect Immun 2002; 70:3959-61; PMID:12065543; http://dx.doi.org/10.1128/IAI.70.7.3959-3961.2002
22. S.Fujigaki, K.Saito, K.Sekikawa, S.Tone, O.Takikawa, H.Fujii, H.Wada, A.Noma, M.Seishima. Lipopolysaccharide induction of indoleamine 2,3-dioxygenase is mediated dominantly by an IFN-gamma-independent mechanism. Euro J Immunol 2001; 31:2313-8; PMID:11477543; http://dx.doi.org/10.1002/1521-4141(200108)31:8%3c2313::AID-IMMU2313%3e3.0.CO;2-S
23. G.Frumento, R.Rotondo, M.Tonetti, G.Damonte, U.Benatti, G.B.Ferrara. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 2002; 196:459-68; PMID:12186838; http://dx.doi.org/10.1084/jem.20020121
24. A.Curti, S.Pandolfi, B.Valzasina, M.Aluigi, A.Isidori, E.Ferri, V.Salvestrini, G.Bonanno, S.Rutella, I.Durelli et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells. Blood 2007; 109:2871-7; PMID:17164341; http://dx.doi.org/10.1182/blood-2006-07-036863
25. D.A.Wainwright, M.Dey, A.Chang, M.S.Lesniak. Targeting tregs in malignant brain cancer:overcoming IDO. Front Immunol 2013; 4:116; PMID:23720663; http://dx.doi.org/10.3389/fimmu.2013.00116
26. B.Baban, P.R.Chandler, M.D.Sharma, J.Pihkala, P.A.Koni, D.H.Munn, A.L.Mellor. IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J Immunol 2009; 183:2475-83; PMID:19635913; http://dx.doi.org/10.4049/jimmunol.0900986
27. I.H.Chan, V.Wu, M.Bilardello, E.Mar, M.Oft, P.Van Vlasselaer, J.B.Mumm. The potentiation of IFN-gamma and induction of cytotoxic proteins by pegylated IL-10 in human CD8 T cells. J Interferon Cytokine Res 2015; PMID:26309093; http://dx.doi.org/10.1089/jir.2014.0221
28. M.W.Taylor, G.S.Feng. Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J:Off Pub Federat Am Soc Exp Biol 1991; 5:2516-22; PMID:1907934
29. B.Jurgens, U.Hainz, D.Fuchs, T.Felzmann, A.Heitger. Interferon-gamma-triggered indoleamine 2,3-dioxygenase competence in human monocyte-derived dendritic cells induces regulatory activity in allogeneic T cells. Blood 2009; 114:3235-43; PMID:19625705; http://dx.doi.org/10.1182/blood-2008-12-195073
30. S.A.Sarkar, R.Wong, S.I.Hackl, O.Moua, R.G.Gill, A.Wiseman, H.W.Davidson, J.C.Hutton. Induction of indoleamine 2,3-dioxygenase by interferon-gamma in human islets. Diabetes 2007; 56:72-9; PMID:17192467; http://dx.doi.org/10.2337/db06-0617
31. X.Liu, N.Shin, H.K.Koblish, G.Yang, Q.Wang, K.Wang, L.Leffet, M.J.Hansbury, B.Thomas, M.Rupar et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 2010; 115:3520-30; PMID:20197554; http://dx.doi.org/10.1182/blood-2009-09-246124
32. S.Jana, P.Jailwala, D.Haribhai, J.Waukau, S.Glisic, W.Grossman, M.Mishra, R.Wen, D.Wang, C.B.Williams et al. The role of NF-kappaB and Smad3 in TGF-beta-mediated Foxp3 expression. Euro J Immunol 2009; 39:2571-83; PMID:19701891; http://dx.doi.org/10.1002/eji.200939201
33. S.Fu, N.Zhang, A.C.Yopp, D.Chen, M.Mao, D.Chen, H.Zhang, Y.Ding, J.S.Bromberg. TGF-beta induces Foxp3 + T-regulatory cells from CD4 + CD25 - precursors. Am J Transplant 2004; 4:1614-27; PMID:15367216; http://dx.doi.org/10.1111/j.1600-6143.2004.00566.x
34. D.Q.Tran, H.Ramsey, E.M.Shevach. Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood 2007; 110:2983-90; PMID:17644734; http://dx.doi.org/10.1182/blood-2007-06-094656
35. Q.Chen, Y.C.Kim, A.Laurence, G.A.Punkosdy, E.M.Shevach. IL-2 controls the stability of Foxp3 expression in TGF-beta-induced Foxp3+ T cells in vivo. J Immunol 2011; 186:6329-37; PMID:21525380; http://dx.doi.org/10.4049/jimmunol.1100061
36. P.Van Vlasselaer, B.Borremans, U.van Gorp, J.R.Dasch, R.De Waal-Malefyt. Interleukin 10 inhibits transforming growth factor-beta (TGF-beta) synthesis required for osteogenic commitment of mouse bone marrow cells. J Cell Biol 1994; 124:569-77; PMID:8106554; http://dx.doi.org/10.1083/jcb.124.4.569
37. K.Nakagome, M.Dohi, K.Okunishi, R.Tanaka, J.Miyazaki, K.Yamamoto. In vivo IL-10 gene delivery attenuates bleomycin induced pulmonary fibrosis by inhibiting the production and activation of TGF-beta in the lung. Thorax 2006; 61:886-94; PMID:16809410; http://dx.doi.org/10.1136/thx.2005.056317
38. R.N.Fedorak, A.Gangl, C.O.Elson, P.Rutgeerts, S.Schreiber, G.Wild, S.B.Hanauer, A.Kilian, M.Cohard, A.LeBeaut et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The interleukin 10 inflammatory bowel disease cooperative study group. Gastroenterology 2000; 119:1473-82; PMID:11113068; http://dx.doi.org/10.1053/gast.2000.20229
39. S.Schreiber, R.N.Fedorak, O.H.Nielsen, G.Wild, C.N.Williams, S.Nikolaus, M.Jacyna, B.A.Lashner, A.Gangl, P.Rutgeerts et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's disease IL-10 cooperative study group. Gastroenterology 2000; 119:1461-72; PMID:11113067; http://dx.doi.org/10.1053/gast.2000.20196
40. K.Asadullah, W.D.Docke, M.Ebeling, M.Friedrich, G.Belbe, H.Audring, H.D.Volk, W.Sterry. Interleukin 10 treatment of psoriasis:clinical results of a phase 2 trial. Arch Dermatol 1999; 135:187-92; PMID:10052405; http://dx.doi.org/10.1001/archderm.135.2.187
41. H.Tilg, C.van Montfrans, A.van den Ende, A.Kaser, S.J.van Deventer, S.Schreiber, M.Gregor, O.Ludwiczek, P.Rutgeerts, C.Gasche et al. Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut 2002; 50:191-5; PMID:11788558; http://dx.doi.org/10.1136/gut.50.2.191
42. F.N.Lauw, D.Pajkrt, C.E.Hack, M.Kurimoto, S.J.van Deventer, T.van der Poll. Proinflammatory effects of IL-10 during human endotoxemia. J Immunol 2000; 165:2783-9; PMID:10946310; http://dx.doi.org/10.4049/jimmunol.165.5.2783
43. R.B.Holmgaard, D.Zamarin, D.H.Munn, J.D.Wolchok, J.P.Allison. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med 2013; 210:1389-402; PMID:23752227; http://dx.doi.org/10.1084/jem.20130066